这是中国药企第一次率先引领某一创新疗法的成药性。《柳叶刀》权威见证,科济药业全球首个在实体瘤中开展的CAR-T细胞治疗随机对照试验(CT041-ST-01试验)取得成功,确证舒瑞基奥仑赛(Claudin18.2 CAR-T)相较当前标准治疗在延长PFS方面具有显著优势,疾病进展或死亡风险显著降低63%,成功达成主要终点,OS亦显示出明确临床获益,输注患者死亡风险降低40%。基于这一研究结果的支持,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.